Insmed Q3 Revenue Soars to $524M as BRINSUPRI Guidance Raised to $1.35–1.4B

What happened

Insmed reported third-quarter 2026 total revenues of $524.4 million, driven by BRINSUPRI sales of $400.1 million, a 29% sequential increase, and ARIKAYCE sales of $124.4 million, up 9% year-over-year. Management raised full-year 2026 guidance for BRINSUPRI to $1.35–1.4 billion and for ARIKAYCE to $460–470 million, reflecting stronger-than-expected demand. The company also launched BRINSUPRI tablets in Japan, expanding its international footprint beyond the US, EU, and UK. This performance contrasts sharply with earlier investor concerns about elevated operating expenses and the discontinued hidradenitis suppurativa program, signaling that the core respiratory franchise is gaining substantial traction. The results validate the blockbuster launch narrative and provide concrete evidence that BRINSUPRI is scaling well beyond initial expectations.

Implication

The Q3 results directly address the key thesis checkpoint: BRINSUPRI revenue is not only meeting but exceeding the prior full-year guidance, implying full-year sales will likely land near the top of the raised range. The 29% sequential growth indicates robust underlying demand, not just channel filling, and the raised ARIKAYCE guidance provides additional stability to the revenue base. The Japan launch adds a new growth vector that the market had not fully priced, potentially contributing meaningfully in 2027 and beyond. With revenue scaling faster than expected, the path to cash-flow positivity in 2027 becomes more credible, reducing the risk of near-term dilution. However, investors should monitor whether the company can maintain operating expense discipline, as SG&A growth relative to revenue will determine margin expansion and sustainability of the upward re-rating.

Thesis delta

The investment thesis strengthens materially as BRINSUPRI's Q3 performance and raised full-year guidance exceed the base-case assumption of at least $1.0 billion in 2026 revenue. The central uncertainty now shifts from demand trajectory to cost management and pipeline execution, with the base value likely moving toward the prior bull scenario. The key risk remains whether SG&A growth decelerates enough to allow operating leverage, but the revenue outperformance provides a larger buffer and validates the commercial strategy.